Trial Profile
The safety and efficacy of radiofrequency ablation and cryoablation in patients with atrial fibrillation (AF) under anticoagulant therapy with apixaban
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms J-HIT
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 04 Sep 2015 New trial record